Neurofibromatosis Therapeutic Acceleration Program (NTAP) recognizes that an international effort is required to address the unique challenges associated with rare disease drug development. Given the relatively low prevalence and high variability seen with cutaneous neurofibromas (cNFs), a critical mass of patients and researchers is required that can only be achieved through collaborative, multi-center efforts.

We work with several academic and clinical consortia to advance therapies for pNF, including: